Navigation Links
Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units
Date:11/10/2008

d, that third parties on whom we depend will perform as anticipated, or that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and therapeutic hypothermia devices and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our ability to successfully accelerate the commercialization of our therapeutic hypothermia devices and launch new devices within the timeframes contemplated, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2008 Cardium Therapeutics, Inc. All rights reserved.

For Terms of Use Privacy Policy, please visit http://www.cardiumthx.com.

Cardium Therapeutics(TM) and Generx(TM) are trademarks of Cardium
Therapeutics, Inc. Tissue Repair(TM), Gene Activated Matrix(TM), GAM(TM) and Excellarate(TM)

are trademarks of Tissue Repair Company. InnerCool Therapies(R), InnerCool(R), Celsius Control System(R),

RapidBlue(TM
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Cardium Announces FDA 510(K) Clearance of InnerCools RapidBlue(TM) Endovascular System
2. ITGI Medical Received a CE Mark for its Second Pericardium Covered Stent - AneuGraft(R) - for Tortuous Vessels
3. Cardium Announces InnerCools New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification
4. Cardium Announces Follow-On Direct Investment by Institutional Investor
5. Cardium Selected for Inclusion in Russell Microcap Index
6. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
7. Cardium Launches New AWARE Clinical Study Website
8. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
9. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
10. Cardium Reports on First Quarter 2008 Highlights and Financial Results
11. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... NY (PRWEB) September 23, 2014 Marktech ... of deep ultra violet emitters in the 280 nm ... standard UV emitters which range from 280nm to 405nm. ... and water sanitation as well as curing. Mark Campito, ... line of special interest to manufacturers is that we ...
(Date:9/23/2014)... New spin-out from Cancer ... Innovation Capital and Johnson & Johnson Development Corporation  ... focused on harnessing the potential of circulating tumour ... treatment, today announced it has raised £4m in ... including Cambridge Innovation Capital and Johnson & Johnson ...
(Date:9/22/2014)... , September 22, 2014 ... announced the addition of the "Global Biotechnology ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Biotechnology ... added to a system to detect and examine ... are generally used in laboratories to prepare, collect, ...
(Date:9/22/2014)... new star-shaped molecule made up of interlocking rings, which is ... , Known as a ,Star of David, molecule, scientists have ... a century and the team,s findings are published in the ... molecular triangles, entwined about each other three times into a ... is 114 atoms in length around the perimeter. The molecular ...
Breaking Biology Technology:Marktech Introduces its New Line of Deep UV Emitters 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 3
... N.J., June 27 Wyeth (NYSE: WYE ) ... Executive,Officer, has assumed the additional position of Chairman of ... a previously announced election by the,Company,s Board of Directors, ... in April 2006 when Mr. Poussot was promoted to ...
... and Received over $235 Million, SOUTH SAN FRANCISCO, ... announced today that the company and,GlaxoSmithKline, Inc. (NYSE: ... conclusion on October 27, 2008, as scheduled. Under the,terms ... up to two of the,compounds in the collaboration for ...
... between 30 and 50 million people. In the infected ... distress syndrome (ARDS). This fatal condition is a massive ... severely damaged. ARDS can be induced by various bacterial ... could be toxic gases that are inhaled or gastric ...
Cached Biology Technology:Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration 2Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration 3Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration 4Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration 5New strategies against bird flu 2
(Date:9/23/2014)... of animals and plants. The central problem in pattern ... a reliable manner to give specific spatial patterns of ... formation is a classic paradigm in developmental biology. Cell ... flag, is caused by a gradient of a signalling ... of the morphogen a "blue", "white" or "red" gene ...
(Date:9/23/2014)... SPRINGS, Florida , September 23, 2014 ... for innovative companies in tech sector position for significant investor ... products & services.  Companies in focus today are: NXT-ID, Inc. ... BABA ), Mobileye N.V. (NYSE: MBLY ... Robotics Ltd. (NASDAQ: RWLK) NXT-ID, Inc. (NASDAQ: ...
(Date:9/22/2014)... GAINESVILLE, Fla. --- Many native species have vanished ... University of Florida scientists have discovered how fossils ... , The key lies in organic materials found ... ancient ecosystems functioned, according to a new study ... the Journal of Herpetology . Pre-human island ...
Breaking Biology News(10 mins):Recreating the stripe patterns found in animals by engineering synthetic gene networks 2Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 2Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 3Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 4Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 5Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 6Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 7Answer to restoring lost island biodiversity found in fossils 2
... GABLES, FL. -- The key to understanding how future hurricanes ... native coastal forests lurks below the surface, according to a ... the familiar mangroves that line the coasts lie hardwood hammocks ... the soils., University of Miami (UM) Ecologist Donald L. DeAngelis, ...
... of Houston (UH) vision scientist has received a $1.85 ... to investigate whether his techniques are more effective than ... could lead to developing a way to earlier diagnose ... assistant professor of vision science and biomedical engineering, uses ...
... warming and instead reduce fossil-fuel use for the sake of ... from the University of Washington and one from the University ... current issue of the journal Nature (Jan. 26) ... trump the environment as a reason to curb the use ...
Cached Biology News:Living on the edge: An innovative model of mangrove-hammock boundaries in Florida 2Sharper imaging in glaucoma focus of $1.85 million NIH grant 2Sharper imaging in glaucoma focus of $1.85 million NIH grant 3Commentary in Nature: Can economy bear what oil prices have in store? 2Commentary in Nature: Can economy bear what oil prices have in store? 3